Trial site
Kochi Health Sciences Center
Kochi, 781-8555, JapanNot linked to an institution yet
- 7running trials
- 1closed trial
The trials here
What the 8 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 1/21 trial
- Status
- Recruiting5 trials
- Active, not recruiting2 trials
- Terminated1 trial
- Lead sponsor
- Bristol-Myers Squibb2 trials
- Daiichi Sankyo2 trials
- Amgen1 trial
- Innovent Biologics (Suzhou) Co. Ltd.1 trial
- National Cancer Center Hospital East1 trial
- and 1 more
Running trials
Recruiting
Study of BK1803 in Healthy Infants
NCT07793513· Phase 3· Tanabe Pharma Corporation· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913· Phase 3· Bristol-Myers Squibb· Source
Contact: Ken Sawada, Site 0142
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· Phase 3· Bristol-Myers Squibb· Source
Contact: Ken Sawada, Site 0161
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843· Phase 3· Innovent Biologics (Suzhou) Co. Ltd.· Source
Active, not recruiting
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934· Phase 3· Daiichi Sankyo· Source
Recruiting
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
NCT04288999· Phase 3· National Cancer Center Hospital East· Source
Contact: Ryo Inada
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error